Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aiming at the Gaucher franchise

After years with a monopoly in the treatment of Gaucher disease, Genzyme Corp. finally could be facing some competition. Oxford GlycoSciences plc last week published data showing that its OGT 918 compound reduces organ volumes associated with the disease. With two other

Read the full 426 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers